冠昊生物(300238) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥122,927,958.21, a decrease of 4.29% compared to ¥128,441,392.59 in the same period last year[5] - Net profit attributable to shareholders increased by 19.36% to ¥21,779,567.39 from ¥18,247,093.30 year-on-year[5] - The net profit after deducting non-recurring gains and losses rose by 25.08% to ¥20,159,987.17 compared to ¥16,117,136.00 in the previous year[5] - Total operating revenue for Q1 2022 was RMB 122,927,958.21, a decrease of 4.0% compared to RMB 128,441,392.59 in the same period last year[21] - The company's net loss for Q1 2022 was RMB 43,642,413.46, an improvement from a net loss of RMB 65,421,980.87 in the previous year[19] - The net profit for Q1 2022 was CNY 21,363,230.14, an increase of 32.4% compared to CNY 16,145,942.21 in Q1 2021[22] - The operating profit for the quarter was CNY 27,587,289.56, up from CNY 23,634,014.51, reflecting a growth of 16.5%[22] - The company reported a total comprehensive income of CNY 20,843,673.76, compared to CNY 16,544,859.18 in Q1 2021, marking an increase of 25.8%[23] - Basic and diluted earnings per share were both CNY 0.08, an increase from CNY 0.07 in the previous year[23] Cash Flow and Investments - The company's cash flow from operating activities decreased by 16.72% to ¥24,690,382.91 from ¥29,648,073.35 in the same period last year[10] - The cash flow from operating activities was CNY 24,690,382.91, down 16.5% from CNY 29,648,073.35 in the same period last year[26] - The company incurred a net cash outflow from investing activities of CNY 2,369,821.21, compared to a net inflow of CNY 3,652,612.25 in the previous year[26] - The company experienced a 96.97% decrease in cash flow from financing activities, resulting in a net cash increase of ¥17,716,277.00 compared to a decrease of ¥24,061,655.30 in the previous year[10] - Cash and cash equivalents at the end of Q1 2022 amounted to RMB 177,024,470.99, an increase of 11.0% from RMB 159,308,193.99 at the beginning of the year[16] - The cash and cash equivalents at the end of the period totaled CNY 177,024,470.99, an increase from CNY 132,140,402.93 at the end of Q1 2021[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,108,065,686.84, an increase of 0.85% from ¥1,098,737,109.35 at the end of the previous year[5] - Total assets as of March 31, 2022, were RMB 1,108,065,686.84, a slight increase from RMB 1,098,737,109.35 at the beginning of the year[19] - Total liabilities decreased to RMB 339,060,131.15 from RMB 350,575,227.44, a reduction of 3.9%[18] - The total equity attributable to shareholders increased to RMB 805,180,563.59 from RMB 783,920,552.56, reflecting a growth of 2.0%[19] Research and Development - Research and development expenses increased by 40.72% to ¥9,770,941.24 from ¥6,943,468.85 year-on-year, indicating a significant investment in R&D[9] - Research and development expenses increased to RMB 9,770,941.24, up 40.7% from RMB 6,943,468.85 in the previous year[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,000[11] Other Operating Income - The company reported a significant increase in government subsidies, contributing to a 241.74% rise in other operating income to ¥132,035.24[9] Inventory and Receivables - Accounts receivable rose to RMB 114,965,319.30, compared to RMB 106,706,485.37 at the start of the year, reflecting a growth of 7.6%[16] - Inventory decreased to RMB 122,972,490.67, down 12.5% from RMB 140,548,422.60 at the beginning of the year[17] Operating Costs - Total operating costs for Q1 2022 were RMB 95,647,842.56, down 10.5% from RMB 106,850,280.30 in Q1 2021[21] - The total operating expenses were CNY 101,503,768.18, slightly down from CNY 103,125,718.28 in Q1 2021[26] Market Activity - The company did not report any significant new product launches or market expansions during this quarter[27]